Skip to Content

Letairis (ambrisentan) Disease Interactions

There are 4 disease interactions with Letairis (ambrisentan):


Endothelin receptor antagonists (applies to Letairis) hepatotoxicity/liver impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Endothelin receptor antagonists (ERAs) have been associated with aminotransferase elevations, hepatotoxicity, and cases of liver failure. Hepatic function should be assessed before treatment initiation and closely monitored during treatment. Therapy should be discontinued if aminotransferase elevations are accompanied by increases in bilirubin, or clinical symptoms of hepatotoxicity such as nausea, vomiting, fever, abdominal pain or jaundice. Treatment should be avoided in patients with elevated aminotransferases at baseline as monitoring for hepatotoxicity may be more difficult. In general, the use of ERAs is not recommended for patients with moderate to severe hepatic impairment.


Ambrisentan (applies to Letairis) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

There is no information on the exposure to ambrisentan in patients with severe renal impairment. Additionally, the impact of hemodialysis on the disposition of ambrisentan has not been studied, hence caution is advised. No dosage adjustment is required in patients with mild or moderate renal impairment.


Endothelin receptor antagonists (applies to Letairis) anemia

Moderate Potential Hazard, Moderate plausibility.

Clinical studies have shown that most endothelin receptor antagonists decrease hemoglobin concentration and hematocrit levels. There are some postmarketing reports of anemia cases which needed blood transfusion. Hemoglobin and hematocrit levels should be measured prior to treatment initiation and should be monitored periodically thereafter. Initiation of therapy is not recommended in patients with clinically significant anemia.


Endothelin receptor antagonists (applies to Letairis) fluid retention

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure

Peripheral edema and fluid retention are known clinical consequences of pulmonary hypertension and also known effects of endothelin receptor antagonists. Caution and monitoring is recommended if these agents are used in patients with underlying left ventricular dysfunction or underlying heart failure, as they have an increased risk for developing significant fluid retention that may need treatment or require discontinuation.

Letairis (ambrisentan) drug interactions

There are 125 drug interactions with Letairis (ambrisentan)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.